Psychedelic medicine: a re-emerging therapeutic paradigm

The paper is a narrative review of contemporary clinical research and selected historical literature; it does not present a systematic search strategy or explicit inclusion/exclusion criteria in the extracted text. Instead, the authors focus on clinically relevant studies that administer psychedelic drugs to patient populations as adjuncts to psychotherapy, and they largely exclude experimental studies conducted in healthy volunteers from detailed consideration. Tupper and colleagues structure the review by drug class and by clinical indication (for example, anxiety in terminal illness, addiction, PTSD). Evidence types surveyed include small randomised controlled trials, within-subject crossover studies, open-label pilot trials, observational studies in ceremonial or community contexts, long-term follow-up reports and re-analyses of earlier mid‑20th-century work. Methodological descriptions of contemporary clinical protocols are provided in qualitative terms (screening, informed consent, therapeutic setting and integration sessions), but the extracted text does not report a formal risk-of-bias assessment, databases searched, date ranges or quantitative meta-analytic methods.

The review summarises recent clinical and observational findings by indication and by substance class. Anxiety: Small controlled and within-subject trials have reported benefits for patients with life‑threatening illness. A Swiss randomised trial enrolled 12 participants to compare higher-dose LSD (200 µg, n = 8) with a low-dose active control (20 µg, n = 4); at two months there were nonsignificant reductions in trait anxiety but significant reductions in state anxiety, and a one‑year follow-up of nine participants showed sustained benefit with no severe or lasting adverse events. A within-subject crossover study of 12 patients with end‑stage cancer compared 0.2 mg/kg psilocybin with 250 mg niacin and reported reduced anxiety and improved mood without clinically significant adverse effects. MDMA-assisted therapy for social anxiety in adults with autism is noted as under study, but results were not reported in the extracted text. Addiction: The authors review historical studies from the 1950s–1960s and more recent pilot work. A New Mexico open-label study of psilocybin-assisted therapy for alcohol dependence recruited 10 participants who received motivational enhancement therapy and one or two psilocybin sessions (0.3 mg/kg and, for some, 0.4 mg/kg). Among study completers, self-reported percent drinking days and percent heavy drinking days were reduced by more than half relative to baseline; acute adverse effects included nausea and mild headache, and no lasting harms were reported. A smoking-cessation open-label study with 15 participants combined cognitive behavioural therapy and two or three psilocybin sessions (20 mg/70 kg or 30 mg/70 kg); at six months 12 of 15 participants were abstinent, with cessation outcomes correlating with measures of mystical-type experience and retrospective ratings of personal meaning. Observational work on ayahuasca in ceremonial and community settings, including a 12-person intervention in a Coast Salish First Nations community, showed improvements in mental-health measures and reductions in self-reported substance use at six months without lasting adverse effects. Long-term devotees in Brazilian religious groups were reported to have lower prevalence of substance use and favourable neuropsychological and psychosocial outcomes compared with matched controls, but the authors note challenges in isolating pharmacological effects from ceremonial and contextual factors and variability in ayahuasca preparations. Posttraumatic stress disorder: Two small randomised trials and follow-up work on MDMA-assisted psychotherapy are described. In a US pilot randomised controlled trial of 20 participants with chronic, treatment‑resistant PTSD (mean illness duration 19 years), the experimental group received two MDMA-assisted sessions plus preparatory and integration psychotherapy. Outcomes included a significant and sustained reduction in Clinician-Administered PTSD Scale (CAPS) scores; 83% of the experimental group versus 25% of the placebo group showed a >30% reduction in symptom severity, and some in the experimental arm no longer met DSM‑IV criteria for PTSD. A long-term follow-up of the same cohort found that 74% (14/19) still showed meaningful sustained reductions in CAPS scores at roughly three and a half years, although two patients relapsed. A Swiss crossover trial (n = 12) comparing three full‑dose MDMA sessions with a low-dose active placebo found no serious drug‑related adverse events; CAPS reductions were not statistically significant but self-reported PTSD symptoms (Posttraumatic Diagnostic Scale) were significantly reduced. The text notes that a Vancouver pilot study began in 2015, marking the first Canadian clinical study involving psychedelics in over 40 years. Safety and adverse events: Contemporary controlled studies report mainly transient, manageable adverse effects occurring during drug action such as acute anxiety, increases in heart rate and blood pressure, and delayed-onset headache with psilocybin. MDMA tends to have greater cardiovascular effects while classic psychedelics more commonly provoke acute psychological reactions. Serious long-term harms such as psychosis or Hallucinogen Persisting Perception Disorder (HPPD) are acknowledged as potential risks, but the extracted text reports these events as relatively uncommon and typically associated with unsupervised illicit use; contemporary trials exclude participants with personal or family histories of psychosis or bipolar disorder. The new clinical studies reviewed did not report lasting drug-related harms.

Tupper and colleagues interpret the assembled evidence as preliminary but promising, suggesting that psychedelic-assisted therapies may produce clinically meaningful improvements for some patients with severe or treatment‑resistant conditions. They stress that contemporary studies have addressed many earlier methodological and ethical shortcomings by applying careful screening, obtaining informed consent, using approved protocols and situating drug administration within structured therapeutic contexts that emphasise set and setting. The authors situate these findings relative to earlier research by noting that methodological weaknesses and ethical violations in the mid‑20th century contributed to a long hiatus in clinical work, and that present-day investigators are more cautious in reporting results and in limiting risk. They identify important unanswered questions: elucidation of neuropharmacological mechanisms, differentiation of which psychedelic agents may be optimal for particular disorders, clarification of the best psychotherapeutic adjuncts and dosing regimens, and evaluation of long-term safety and effectiveness in larger, controlled trials. Economic considerations are raised as well — because preliminary evidence suggests these therapies can be relatively time-limited, they may be cost‑effective compared with chronic pharmacotherapy, but this requires formal evaluation. Key limitations acknowledged in the extracted text include small sample sizes, the prevalence of open‑label and pilot designs, heterogeneous interventions and contexts (particularly for plant-based preparations such as ayahuasca), and the lack of large-scale randomised trials. The authors therefore call for continued rigorous clinical research, development of specialist training for health professionals if efficacy is confirmed, and for policy-makers and research funders to remain open to investigating these approaches despite regulatory and public-perception barriers.

Renewed scientific enquiry into psychedelic medicine is generating new knowledge about pharmacologic agents long used in cultural and ceremonial contexts. The authors argue that if further evidence accumulates regarding therapeutic value, medical education and specialised clinical training will need to incorporate this knowledge so clinicians can respond to patient queries and deliver treatments safely. They also urge policy-makers and health‑system decision-makers to consider the evolving evidence base; current international drug‑scheduling classifications and public misconceptions complicate human research, but continued medical research may yield new treatment options for patients who do not benefit from existing therapies. The re‑emerging paradigm of psychedelic medicine may therefore reopen clinical and therapeutic possibilities that have been closed for decades.